The supplemental data was not included in the main text purely due to considerations of space. Table S1A provides the data concerning the Mass Spectrometry experiments and the identification of PARP-1. The number of peptides identified and the percentage coverage of the protein are given. This is referred to in the text and relates to Figure 5A . Table S1B provides the peptide sequence for the PARP-1 peptides identified in the Mass spectrometric experiments. This is referred to in the text and relates to Figure  5A and provided for more full disclosure and completeness. 
provides the data concerning the Mass Spectrometry experiments and the identification of PARP-1. The number of peptides identified and the percentage coverage of the protein are given. This is referred to in the text and relates to Figure 5A . Table S1B provides the peptide sequence for the PARP-1 peptides identified in the Mass spectrometric experiments. This is referred to in the text and relates to Figure  5A and provided for more full disclosure and completeness. Table S2 gives the EC 50 for latonduine inhibition of members of the PARP family. Showing the potent inhibition of PARP-3. This table is linked to figure 6 of the paper. 
SUPPLEMENTARY FIGURE LEGENDS
Supplementary 
Supplementary Table 2 . Table of EC 50 for the effect of latonduine and ABT888 on the PARPs tested in parts b to g. Data is the combination of three separate experiments and is presented as the mean.
Supplementary Figure 1
Supplementary figure 1 Coomaisse gel of biolatonduine pulldown used to isolate PARP as a target protein. CFBE cells were lysed and split in two aliquots. One was incubated with streptavidin beads that had previously been treated with biotin control (CON) and the other was incubated with streptavidin beads and biotinylated latonduine (BIOLAT).
In the Mass spectrometric experiments the entire lanes for both con and biolat were excised and digested for mass spectrometry. All proteins identified in the control were subtracted from the proteins identified in the biolat lane. Hence only those unique to the biolat lanes were considered (see arrowheads). Note a similar pulldown was performed for figure 5A except that the pulldown underwent SDS PAGE for immunoblotting and that the last wash was also run on the gel as a further control. Band B Band C Treatment designated 0%. Then after normalization to tubulin each band in the other treatments was compared to and given a value relative to the intensity obtained for the latonduine alone treatment.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Differential scanning fluorimetry
Differential scanning fluorimetry was performed using an Mx3005P instrument (Stratagene) as described previously (Sampson et al., 2011) To determine if latonduine directly binds to CFTR, differential scanning fluorimetry using soluble NBD-1 and Sypro-orange was undertaken ( Figure 4C ). This assay relies on the ability of compounds that directly bind to CFTR it unfolds at a higher temperature due to being stabilized by a compound acting as a pharmacological chaperone (Sampson et al., 2011) . In these experiments ATP (2mM) is used as a positive control and gives a positive temperature shift of 5 o C whereas latonduine 100mM did not give stabilization for both wild type and F508del-NBD-1.
Recombinant PARPs
The recombinant PARPs used were as follows: full-length PARP-1: Human Poly (ADPRibose) Polymerase (PARP) 
Isolation of oroidin alkaloids from Stylissa massa
Frozen Stylissa massa (~28 g, wet) was macerated and extracted twice with MeOH. The solvent was removed under reduced pressure and the resulting extract was resuspended in MeOH (100 mL), which was loaded onto an HP-20 column (50 mL), which had been pre-equilibrated with 150 mL each of Me2CO, and MeOH. 1 mg) was purified using RP-HPLC (gradient: start, 25% MeOH/H 2 O held for 9.5 min, ramp to 50% MeOH/H 2 O over 73.0 min, ramp to 100% MeOH over 7.5 min, held at 100% MeOH for 15.0 min). Debromohymenialdisine (2.0 mg) and an inseparable 4:1 mixture of (10Z)-and (10E)-debromoaxinohydantoin (0.5 mg) eluted with retention times of 16.3 and 25.0 min respectively. Fraction RAK01-14H (11.4 mg) from the Sep-Pak ® fractionation was also purified using RP-HPLC HPLC (gradient: start, 10% MeOH/H 2 O held for 10.0 min, ramp to 30% MeOH/H 2 O over 60.0 min, ramp to 100% MeOH over 10.0 min, held at 100% MeOH for 10.0 min,) to give monobromophakellin (1.7 mg), aldisine (0.7 mg) and debromohymenialdisine (1.5 mg) with retention times of 22.1, 31.0 and 52.0 min respectively. Debromohymenialdisine (6.1 mg) also crystallized from redissolved RAK01-14H. All compounds were identified using 1D-and 2D-NMR experiments ( 1 H, 13 C, DEPT-135, COSY, HSQC, HMBC and ROESY experiments) and their structures were confirmed by comparison of their spectroscopic data with published data.
Measurement of cytotoxicity
Toxicity of the oroidins and latonduines were tested using the CellTiter-Glo assay from Promega, which monitors cell viability by detecting ATP levels as luciferin-luciferase bioluminescence (25) . Briefly, each compound was dissolved in DMSO, diluted in cell culture medium to a final concentration of 1-300 µM (DMSO < 1%), and dispensed into 96-well microplates as 50-µl aliquots containing 15,000 BHK cells/well. After incubation at 37°C in a 5% CO 2 incubator for 24 h, cells were incubated for 1 h with reagents from the kit as recommended by the manufacturer. Luminescence was detected using an automated microplate reader (FLUOstar OPTIMA, BMG Labtech, Germany) and normalized to the control group that received only vehicle (DMSO). Cytotoxicity was calculated as the % decrease in luminescence relative to controls without drug. Three independent cytotoxicity assays were carried out at each drug concentration on different days.
Preparation of a biotinylated analogue of latonduine A
Latonduine A (2 mg, 5.36 µmol) was dissolved in 1 ml dry DMF under Ar. K 2 CO 3 (9 mg) and N-iodoacetyl-N-biotinylhexylenediamine (6.6 mg, 3.0 equiv.) were added and
